APA (7th ed.) Citation

Surguladze, D., Malaby, J., Prewett, M., Duignan, I., Rutstein, M., Yao, Y., . . . Pytowski, B. (2012). 34 Efficacy of VEGFR2 Targeted mAb Therapy in Preclinical Colorectal Cancer Model Resistant to Anti-VEGF mAb Therapy. European Journal of Cancer, 48, 13. https://doi.org/10.1016/S0959-8049(12)71833-6

Chicago Style (17th ed.) Citation

Surguladze, D., J. Malaby, M. Prewett, I. Duignan, M. Rutstein, Y.M Yao, J.D Schwartz, and B. Pytowski. "34 Efficacy of VEGFR2 Targeted MAb Therapy in Preclinical Colorectal Cancer Model Resistant to Anti-VEGF MAb Therapy." European Journal of Cancer 48 (2012): 13. https://doi.org/10.1016/S0959-8049(12)71833-6.

MLA (9th ed.) Citation

Surguladze, D., et al. "34 Efficacy of VEGFR2 Targeted MAb Therapy in Preclinical Colorectal Cancer Model Resistant to Anti-VEGF MAb Therapy." European Journal of Cancer, vol. 48, 2012, p. 13, https://doi.org/10.1016/S0959-8049(12)71833-6.